Abstract
Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. Conclusions and clinical relevance: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
Original language | English |
---|---|
Article number | 2000025 |
Journal | Proteomics - Clinical Applications |
Volume | 15 |
Issue number | 2-3 |
Early online date | 2021 |
DOIs | |
Publication status | Published - 2021 May 1 |
Subject classification (UKÄ)
- Cancer and Oncology
Keywords
- affinity proteomics
- antibody microarrays
- biomarkers
- cancer
- prostate cancer